| Literature DB >> 24351422 |
Axel C Mühlbacher1, Matthias Stoll, Jörg Mahlich, Matthias Nübling.
Abstract
OBJECTIVES: Patient-centered health care and shared decision making are of increasing importance in the management of AIDS/HIV patients and require an intensive consideration of patient preferences. The present study assesses expectations and needs of patients from the physician point of view. The aim of this study was to compare patient and physician perspectives of relevant aspects of treatment quality such as effectiveness, quality of life and further treatment options.Entities:
Year: 2013 PMID: 24351422 PMCID: PMC3866604 DOI: 10.1186/2191-1991-3-30
Source DB: PubMed Journal: Health Econ Rev ISSN: 2191-1991
Mean importance of therapy characteristics assessed by physicians taking the view of their patients and by the patients themselves
| | ||
|---|---|---|
| 85 | 89 | Drug improves physical state (e.g. better mobility, pain relief) |
| 84 | 94 | Drug has very high efficacy (reduction of viral load) |
| 76 | 82 | Drug allows for improved mobility (e.g. longer journeys possible) |
| 73 | 85 | Long duration of efficacy following application |
| 62 | 88 | Drug allows further therapy options (in the future) |
| 60 | 90 | Drug does not generate resistance |
| 92 | 89 | Drug does not or does not affect appearance much (disease not visible, e.g. by fat redistribution) |
| 57 | 30 | Pregnancy is allowed during treatment period |
| 56 | 80 | Drug can be used also in case of comorbidities |
| 90 | 94 | Self-application of the drug (at home or on-the-go) is possible |
| 86 | 82 | Flexible application during course of the day (e.g. delay of 1 hour is possible) |
| 83 | 85 | Drug can be taken along without problems (transportation) |
| 81 | 73 | Inconspicuous drug intake (discreet, unnoticed by environment) |
| 77 | 73 | Drug has to be taken only once daily |
| 76 | 84 | Long term use of the drug is possible |
| 69 | 75 | Drug does not cause additional costs for patient (no extra payment) |
| 68 | 71 | Treatment does not require much time (waiting time, time for treatment) |
| 47 | 51 | Therapy-free intervals/treatment breaks are possible |
| 35 | 60 | Dosing of drug may vary according to current health state |
Results of the present study, Results of the previous study [12], bold: attribute used in DCE.
Physician characteristics, professional experience and knowledge of preferences
| N | 131 physicians |
| Gender | |
| Male | 70% |
| Female | 30% |
| Completion of survey | |
| Paper and pencil | 88% |
| Online | 12% |
| Year of licensure | |
| Mean | 1993 |
| 1990 or earlier | 33% |
| 1991-1999 | 46% |
| 2000 or later | 21% |
| Knowledge about patient preferences | |
| Very good | 34% |
| Good | 60% |
| Medium | 5% |
| Not so good | 1% |
Treatment characteristics for Discrete Choice experiment
| Life expectancy | Maximal increase | Moderate increase |
| Long term side-effects | Improbable (<20% of patients) | Possible (≥20% of patients) |
| Flexibility of dosing | Max. 3 tablets/day | ≥4 tablets/day |
| Physical quality of life | Diarrhea, nausea less frequent | Diarrhea, nausea more frequent |
| Emotional quality of life | Disease not obvious for others | Disease obvious for others |
| Social quality of life | Participation in social life possible | Participation in social life restricted |
Results of random effect logit model (Discrete Choice Experiment; negative pole as reference group)
| Life expectancy: maximum increased | 0.846 | 0.265 | ** | -373.0 |
| Long term side-effects improbable (<20%) | 0.831 | 0.224 | *** | -374.5 |
| Flexibility of dosing: max. 3 tablets/day | 0.635 | 0.261 | * | -370.3 |
| Physical quality of life: diarrhea, nausea less frequent | 1.925 | 0.256 | *** | -402.7 |
| Emotional quality of life: disease not obvious for others | 4.003 | 0.269 | *** | -604.8 |
| Social quality of life: participation in social life possible | 1.947 | 0.269 | *** | -402.1 |
| Model constant | -5.316 | 0.417 | *** |
***p < 0.001, **p < 0.01, *p < 0.05.
Model parameters:
LR Chi2 (df = 6) = 715.90.
Log likelihood = -367.7.
Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***).
% correctly classified = 85.0%.
Figure 1Coefficients of Discrete Choice Experiment (positive pole) for physicians (data of present study) and patients (data of previous study,[12]) (normalization of coefficients).
Results of random effect logit model (Discrete Choice Experiment; negative pole as reference group; patients vs. physicians)
| Life expectancy: maximal increase | 0.735 | 0.152 | *** | -717.7 | 0.846 | 0.265 | ** | -373.0 |
| Long term side effects improbable (<20%) | 0.408 | 0.147 | ** | -709.5 | 0.831 | 0.224 | *** | -374.5 |
| Flexibility of dosing: max. 3 tablets/day | 0.454 | 0.151 | ** | -710.1 | 0.635 | 0.261 | * | -370.3 |
| Physical quality of life: diarrhoea, nausea less frequent | 1.611 | 0.152 | *** | -769.4 | 1.925 | 0.256 | *** | -402.7 |
| Emotional quality of life: disease not obvious for others | 2.984 | 0.153 | *** | -981.7 | 4.003 | 0.269 | *** | -604.8 |
| Social quality of life: participation in social life possible | 1.140 | 0.153 | *** | -735.4 | 1.947 | 0.269 | *** | -402.1 |
| Model constant | -3.726 | 0.214 | *** | -5.316 | 0.417 | *** | ||
1) ***p < 0.001, **p < 0.01, Model parameters: Wald Chi2 (df = 6) = 470.81, Log likelihood = -705.7, Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***), Prob ≥ Chi2 = 1.000.
2) ***p < 0.001, **p < 0.01, *p < 0.05; Model parameters: LR Chi2 (df = 6) = 715.90, Log likelihood = -367.7, Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***), % correctly classified = 85.0%.